<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598441</url>
  </required_header>
  <id_info>
    <org_study_id>SCMCIRB-201127</org_study_id>
    <nct_id>NCT01598441</nct_id>
  </id_info>
  <brief_title>Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD)</brief_title>
  <official_title>Multi-centre, Randomized Study of Iloprost Inhaled in Preventing and Treating Reactive Pulmonary Hypertension (RPH) and Pulmonary Hypertensive Crisis (PHC) After Repair of Congenital Heart Diseases (CHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiothoracic Surgical Group of Chinese Society of Pediatric Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to investigate treatment of postoperative pulmonary hypertension by
      iloprost inhalation in children with congenital heart defects. It was a controlled
      single-blind randomized multi-center prospective study in order to explore the efficacy of
      this method in the treatment and prevention of pediatric pulmonary hypertension after
      corrective open-heart surgery for congenital heart defects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives:

        1. To evaluate the effect of iloprost inhaled on postoperative PH after biventricular
           repair for CHD.

        2. To verify the benefits of iloprost inhaled in improving the hemodynamics after
           biventricular repair for CHD.

      Secondary objectives:

        1. To investigate the preventive effect of iloprost inhaled on the life-threatening PHC
           occurring immediately after complex congenital heart surgery or occurring just after
           weaning off cardiopulmonary bypass.

        2. To explore the potential of iloprost inhaled to reduce the early mortality after PHC and
           to decrease the use of ECMO/VAD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total incidence of RPH, PHC or death</measure>
    <time_frame>within 48 hours after surgery</time_frame>
    <description>The primary effective endpoints are reached when any individual components of the primary composite endpoint occur:
RPH lasting for more than 30 mintues; or
PHC at any time; or
death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from base line of pulmonary hemodynamic measurements</measure>
    <time_frame>within 48 hours after surgery</time_frame>
    <description>Pp/Ps
NYHA class function
SvO2
PAO2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>iloprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iloprost nebuliser solution 500 ng/kg inhaled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>distilled water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>aerosolized distilled water 1-2 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iloprost nebuliser solution</intervention_name>
    <description>Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days</description>
    <arm_group_label>iloprost</arm_group_label>
    <other_name>Ventavis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>distilled water</intervention_name>
    <description>1-2 ml aerosolized distilled water inhalation per session</description>
    <arm_group_label>distilled water</arm_group_label>
    <other_name>Treeful</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CHD children who have associated PH risk factors and have accepted biventricular
             repair

          -  Pp/Ps &gt;= 0.75 (before surgery) or Pp/Ps &gt;= 0.5 (after surgery)

        Exclusion Criteria:

          -  severe mitral stenosis

          -  obstructive drainage of pulmonary veins

          -  platelet count &lt; 50,000,000,000/L &amp; obvious bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuomin Xu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou Children's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Hear Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac intensive Care Unit,Department of Thoracic and Cardiovascular Sugery,Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>November 20, 2016</last_update_submitted>
  <last_update_submitted_qc>November 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xu Zhuoming</investigator_full_name>
    <investigator_title>Director of ICU, Department of thoracic and cardiovascular surgery, Shanghai Children's Medical Center</investigator_title>
  </responsible_party>
  <keyword>pulmonary hypertension, pulmonary hypertensive crisis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

